Sanyou Biopharmaceuticals Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sanyou Biopharmaceuticals Co., Ltd. - overview
Established
2015
Location
Shanghai, -, China
Primary Industry
Pharmaceuticals
About
Based in Shanghai, China and founded in 2015, Sanyou Biopharmaceuticals Co. , Ltd. is a pharmaceutical company that focuses on development of innovative monoclonal antibody drugs, providing therapeutic antibody discovery and relevant technology platforms. The company has established global business centers across Asia, North America, and Europe and has filed over 130 invention patents.
It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001. In February 2026, returning investor Shanghai ZJ Bio-Tech Co. , Ltd. and new investor Yanghe Biomedicine Industry Investment partly acquired Sanyou Biopharmaceuticals Co.
, Ltd. from Haier Capital. The company has built an integrated drug development platform, mainly including innovative antibody drugs, target-to-PCC drugs, PCC-to-IND drugs and other research and development platforms, the innovative antibody drug discovery platform include integrated protein and antigen preparation technology, systematic antibody drug functional screening technology, large-capacity phage display full antibody library technology, innovative antibody engineering technology, diversified antibody production technology and integrated genetic engineering antibody library technology, and has self-develop a COVID-19 proteins and antibodies in 2020. The company also provides high-quality proteins, antibodies, cell lines and detection reagents.
The company generates revenue from providing integrated antibody drug development platforms. The funding from Shanghai ZJ Bio-Tech Co. , Ltd. and Yanghe Biomedicine Industry Investment is expected to further optimize Sanyou Biopharmaceuticals Co.
, Ltd. 's governance structure and deepen industrial synergy. With this deal, investors and target company will fully leverage their existing strategic advantages to deepen collaborative research in the field of innovative biopharmaceutical R&D, further shorten the R&D cycle, improve R&D efficiency, and enhance core competitiveness.
Current Investors
Shanghai ZJ Bio-Tech Co., Ltd., Seeking Capital, Haier Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Bioinformatics, Pharmaceutical Research & Development, Medical Software
Website
www.sanyoubio.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Sanyou Biopharmaceuticals Co., Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Sanyou Biopharmaceuticals Co., Ltd. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.